Jamie Goddard

#BREAKING: The U.S. FDA has approved our medicine for the treatment of allergic fungal rhinosinusitis (AFRS) in certain people aged 6 years or older. Read more: bit.ly/4c7LfXJ CC: @sanofi

The FDA granted accelerated approval for our medicine to treat relapsed/refractory #multiplemyeloma after at least four prior lines of therapy. This milestone reflects our relentless commitment to make a meaningful impact in the lives of people living with multiple myeloma.

#Breaking: The U.S. FDA approved our medicine for #BullousPemphigoid (BP). Learn what this approval means for adults living with BP, a chronic skin disease.  CC: @Sanofi

Today, we shared interim results from our ongoing Phase 2 trial investigating the ability of our investigational treatments to improve the quality of weight loss when added to GLP-1 treatment. Read more here. bit.ly/4mEWg5s

Announcing an in-licensing agreement for an investigational, novel dual GLP-1/GIP receptor agonist that will enable synergy and flexibility across our broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities and long-term health.

Exciting news! Our medicine for #ChronicSpontaneousUrticaria (CSU) is now FDA-approved. This helps fulfill an unmet need for the more than 300,000 eligible people living with this condition in the U.S. CC: @Sanofi

We're excited to return to #ATS2024 with @Sanofi and share our latest advancements in #COPD and #asthma, including 17 new abstracts. Learn more about our commitment to improving outcomes for people living with these serious respiratory diseases: bit.ly/3V5vSpV

We're committed to pushing the boundaries of science in the auditory space to help people living with hearing loss. Our pioneering genetic medicines research and technologies have the opportunity to accelerate potential treatments for hearing disorders. #ARO

We are honored to have supported the @AAOHNS Annual Meeting, an important opportunity for otolaryngologist-head and neck surgeons from around the world to convene and share the latest advancements in research and effective practices within the field. #OTOMTG23

The U.S. FDA has accepted our application for Priority Review for our medicine for children ages 1 – 11 with eosinophilic esophagitis (#EoE), a disease driven in part by type 2 inflammation that damages the esophagus. @SanofiUS

We are pleased to share that @JAMAOphth has published data from our Phase 2 clinical trial evaluating our treatment for people living with wet age-related macular degeneration. Learn more here: bit.ly/44W2PY6 #Ophthalmology